Sign Up for Our E-Newsletter

In The News

Update: Cologuard Stool DNA Screening Test

Posted on October 31, 2014

Cologuard 1_small

This month, the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Decision for Cologuard, making it the first FDA-approved stool DNA test for the detection of colon cancer and precancer covered for Medicare patients throughout the country. This came after the exciting US FDA approval of Cologuard in August. You may have heard some buzz earlier this week about Cologuard’s availability to the public. It turns out some of these facts were incorrect. In order to eliminate any confusion around this new colon cancer screening test, we’re setting the record straight. Check out our updated FAQ to find out what you need to know. Read more

NEW RESEARCH: Young-Onset Colon Cancer on the Rise

Posted on October 24, 2014

iStock_000020861529XSmall

We continue to expand our efforts in getting young-onset colon cancer on map through our Never Too Young campaign and recent whitepaper because we’re invested in this topic and how it impacts our community. It’s exciting to see that as awareness grows about the increased incidence rates of colon cancer in the under 50 population, more researchers are taking this issue under their wing as an area of exploration. We attended the annual meeting of the American College of Gastroenterology this week and learned about the work investigators at Weill Cornell Medical College in New York are doing on the topic. Read more

Colon Health Alert: FDA Approves New CRC Screening Test

Posted on August 15, 2014

Colon Health Alert_square

This week, the U.S. Food and Drug Administration (FDA) approved Cologuard, the first stool-based colon screening test that detects the presence of blood and altered DNA that may indicate certain kinds of abnormal growths related to colon cancer or precursors to cancer. In a study of 10,000 people of average risk for colon cancer, Cologuard reportedly was able to accurately detect cancer 92% of the time when it was present in an individual’s body. Read more

News: FDA Approves New CRC Drug for Phase I Clinical Trial

Posted on July 31, 2014

Research 1_small

Exciting news in the colon cancer world! Last week, the experimental drug MGD007 was cleared by the FDA for Phase I clinical trials in colon cancer, scheduled to start later this year. MGD007 is different from other drugs currently available because it kills cancer cells in a different way. Specifically, it binds to a protein on immune system cells (or T-cells) and directs them to kill cells that express a protein found on 95% of primary and metastatic colon cancer cells. Read more

Prevention News You Can Use

Posted on July 21, 2014

bluestar_small

Study: Racial Disparity in Colon Cancer

Dr. John M. Carethers, a researcher at the University of Michigan Medical School, has conducted a study that may lead to concrete conclusions as to why African Americans have lower colon cancer survival rates. The study included African American and Caucasian colon cancer patients with a goal of determining if the groups had a genetic marker called microsatellite instability (MSI). Patients with MSI tumors have higher survival rates, and it was found that 14% of Caucasians and 7% of African-Americans had MSI colon cancer. Read more

css.php